Free Trial

Milestone Pharmaceuticals Q2 2023 Earnings Report

Milestone Pharmaceuticals logo
$0.70 -0.05 (-7.24%)
As of 04/4/2025 04:00 PM Eastern

Milestone Pharmaceuticals EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Milestone Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Milestone Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Milestone Pharmaceuticals Earnings Headlines

Research Analysts Set Expectations for MIST Q1 Earnings
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen
See More Milestone Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (NASDAQ:MIST), a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

View Milestone Pharmaceuticals Profile

More Earnings Resources from MarketBeat